title: NICE guidance on dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma.
authors.affiliation: National Institute for Health and Care Excellence, London SW1A 2BU, UK. Electronic address: Helen.Tucker@nice.org.uk.
authors.forename: Helen
authors.initials: H
authors.lastname: Tucker
authors.affiliation: National Institute for Health and Care Excellence, London SW1A 2BU, UK.
authors.forename: Nwamaka
authors.initials: N
authors.lastname: Umeweni
authors.affiliation: National Institute for Health and Care Excellence, London SW1A 2BU, UK.
authors.forename: Janet
authors.initials: J
authors.lastname: Robertson
authors.affiliation: National Institute for Health and Care Excellence, London SW1A 2BU, UK.
authors.forename: Jane
authors.initials: J
authors.lastname: Adam
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics* / Q000556:secondary; D009154:Mutation / Q000235:genetics*; D010091:Oximes / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D011379:Prognosis; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; D010091:Oximes; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; C561627:dabrafenib